Sulaiman Al Habib 9M 2024 profit rises 12% to SAR 1.7B; Q3 at SAR 595.5M

03/11/2024 Argaam Exclusive

View other reports

Dr. Sulaiman Al Habib Medical Services Group posted a 12% profit rise in the first nine months of 2024 to SAR 1.70 billion, compared to SAR 1.52 billion in the prior-year period.

Financials (M)

Item	9m 2023	9m 2024	Change‬
Revenues	7,021.95	8,071.59	14.9 %
Gross Income	2,401.89	2,747.45	14.4 %
Operating Income	1,561.47	1,732.13	10.9 %
Net Income	1,521.00	1,701.52	11.9 %
Average Shares	350.00	350.00	-
EPS (Riyals)	4.35	4.86	11.9 %

The profit rise was mainly driven by a 14.95% year-on-year (YoY) rise in revenue to SAR 8.07 billion, as a result of the growth in the hospitals and pharmacies segments and an increase in the number of patients.

Earnings before interest, taxes, depreciation, and amortization (EBITDA) rose 11.62% YoY to SAR 2.13 billion. Meanwhile, EBITDA margin declined to 26.48% during the nine-month period from 27.26% a year earlier.

The company’s net profit margin shrank to 21.08% from 21.66% in 9M 2023.

Current Quarter Comparison (M)

Compared With The

Item	Q3 2023	Q3 2024	Change‬
Revenues	2,442.81	2,976.56	21.9 %
Gross Income	843.43	992.10	17.6 %
Operating Income	552.09	624.38	13.1 %
Net Income	544.77	595.54	9.3 %
Average Shares	350.00	350.00	-
EPS (Riyals)	1.56	1.70	9.3 %

Item	Q2 2024	Q3 2024	Change‬
Revenues	2,573.62	2,976.56	15.7 %
Gross Income	878.03	992.10	13.0 %
Operating Income	551.67	624.38	13.2 %
Net Income	555.03	595.54	7.3 %
Average Shares	350.00	350.00	-
EPS (Riyals)	1.59	1.70	7.3 %

The third-quarter net profit grew 9% to SAR 595.5 million, from SAR 544.7 million in Q3 2023.

The topline jumped 21.85% YoY % to SAR 2.97 billion, as a result of the growth in the hospitals and pharmacies segments and an increase in the number of patients

EBITDA rose 14.3% YoY to SAR 772,75 million, while EBITDA margin dropped to 25.96% from 27.68% in Q3 2023.

Compared to Q2 2024, net earnings rose 7.3% from SAR 555 million as revenue leapt 15.66% quarter-on-quarter on increased number of patients.

Shareholders’ equity, after minority interest, reached SAR 6.99 billion as of Sept. 30, 2024, up from SAR 6.39 billion a year earlier.

View More Financial Results

Financial results (Million)

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2015	-	-	-	-	-	-
Q2 2015	-	-	-	-	-	-
Q3 2015	-	-	-	-	-	-
Q4 2015	-	-	-	-	-	-
2015	5,122.63	-	2,215.70	-	1,348.96	-
Q1 2016	-	-	-	-	-	-
Q2 2016	-	-	-	-	-	-
Q3 2016	-	-	-	-	-	-
Q4 2016	-	-	-	-	-	-
2016	4,868.00	(5.0 %)	1,888.69	(14.8 %)	924.66	(31.5 %)
Q1 2017	-	-	-	-	-	-
Q2 2017	-	-	-	-	-	-
Q3 2017	-	-	-	-	-	-
Q4 2017	-	-	-	-	-	-
2017	4,379.03	(10.0 %)	1,265.38	(33.0 %)	655.26	(29.1 %)
Q1 2018	1,169.41	-	361.40	-	221.01	-
Q2 2018	1,068.31	-	290.57	-	153.73	-
Q3 2018	1,145.35	-	354.30	-	215.17	-
Q4 2018	1,204.57	-	355.74	-	211.62	-
2018	4,587.63	4.8 %	1,362.01	7.6 %	801.52	22.3 %
Q1 2019	1,227.90	5.0 %	404.20	11.8 %	248.18	12.3 %
Q2 2019	1,157.19	8.3 %	334.70	15.2 %	163.58	6.4 %
Q3 2019	1,226.74	7.1 %	348.97	(1.5 %)	192.48	(10.5 %)
Q4 2019	1,404.45	16.6 %	435.67	22.5 %	263.49	24.5 %
2019	5,016.28	9.3 %	1,523.54	11.9 %	867.72	8.3 %
Q1 2020	1,343.34	9.4 %	399.85	(1.1 %)	258.61	4.2 %
Q2 2020	1,203.01	4.0 %	359.86	7.5 %	203.31	24.3 %
Q3 2020	1,623.91	32.4 %	558.89	60.2 %	323.89	68.3 %
Q4 2020	1,691.35	20.4 %	545.81	25.3 %	329.05	24.9 %
2020	5,861.61	16.9 %	1,864.41	22.4 %	1,114.86	28.5 %
Q1 2021	1,694.79	26.2 %	549.42	37.4 %	349.63	35.2 %
Q2 2021	1,751.21	45.6 %	551.02	53.1 %	339.73	67.1 %
Q3 2021	1,836.35	13.1 %	586.42	4.9 %	380.54	17.5 %
Q4 2021	1,968.13	16.4 %	643.38	17.9 %	396.25	20.4 %
2021	7,250.47	23.7 %	2,330.23	25.0 %	1,466.15	31.5 %
Q1 2022	1,990.86	17.5 %	658.56	19.9 %	422.09	20.7 %
Q2 2022	2,014.01	15.0 %	670.88	21.8 %	414.75	22.1 %
Q3 2022	2,052.19	11.8 %	681.63	16.2 %	436.09	14.6 %
Q4 2022	2,253.68	14.5 %	737.07	14.6 %	427.56	7.9 %
2022	8,310.74	14.6 %	2,748.14	17.9 %	1,700.49	16.0 %
Q1 2023	2,306.88	15.9 %	783.64	19.0 %	510.57	21.0 %
Q2 2023	2,272.27	12.8 %	774.83	15.5 %	498.81	20.3 %
Q3 2023	2,442.81	19.0 %	843.43	23.7 %	552.09	26.6 %
Q4 2023	2,486.49	10.3 %	868.16	17.8 %	534.18	24.9 %
2023	9,508.44	14.4 %	3,270.05	19.0 %	2,095.65	23.2 %
Q1 2024	2,521.41	9.3 %	877.33	12.0 %	556.08	8.9 %
Q2 2024	2,573.62	13.3 %	878.03	13.3 %	551.67	10.6 %
Q3 2024	2,976.56	21.9 %	992.10	17.6 %	624.38	13.1 %

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2014	-	-	-	-	-	-
2015	5,122.63	-	2,215.70	-	1,348.96	-
2016	4,868.00	(5.0 %)	1,888.69	(14.8 %)	924.66	(31.5 %)
2017	4,379.03	(10.0 %)	1,265.38	(33.0 %)	655.26	(29.1 %)
2018	4,587.63	4.8 %	1,362.01	7.6 %	801.52	22.3 %
2019	5,016.28	9.3 %	1,523.54	11.9 %	867.72	8.3 %
2020	5,861.61	16.9 %	1,864.41	22.4 %	1,114.86	28.5 %
2021	7,250.47	23.7 %	2,330.23	25.0 %	1,466.15	31.5 %
2022	8,310.74	14.6 %	2,748.14	17.9 %	1,700.49	16.0 %
2023	9,508.44	14.4 %	3,270.05	19.0 %	2,095.65	23.2 %

Profit Performance (Million)

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
Q1 2015	-	-	-	-	-	-
Q2 2015	-	-	-	-	-	-
Q3 2015	-	-	-	-	-	-
Q4 2015	-	-	-	-	-	-
2015	1,328.87	-	3.80	-	1,328.87	3.80
Q1 2016	-	-	-	-	-	-
Q2 2016	-	-	-	-	-	-
Q3 2016	-	-	-	-	-	-
Q4 2016	-	-	-	-	-	-
2016	1,009.94	(24.0 %)	2.89	-	1,009.94	2.89
Q1 2017	-	-	-	-	-	-
Q2 2017	-	-	-	-	-	-
Q3 2017	-	-	-	-	-	-
Q4 2017	-	-	-	-	-	-
2017	656.17	(35.0 %)	1.87	-	656.17	1.87
Q1 2018	216.53	-	0.62	-	216.53	0.62
Q2 2018	151.51	-	0.43	-	151.51	0.43
Q3 2018	207.93	-	0.59	-	207.93	0.59
Q4 2018	225.34	-	0.64	-	225.34	0.64
2018	801.31	22.1 %	2.29	-	801.31	2.29
Q1 2019	234.08	8.1 %	0.67	-	234.08	0.67
Q2 2019	167.97	10.9 %	0.48	-	167.97	0.48
Q3 2019	198.00	(4.8 %)	0.57	-	198.00	0.57
Q4 2019	270.18	19.9 %	0.77	-	270.18	0.77
2019	870.23	8.6 %	2.49	-	870.23	2.49
Q1 2020	246.60	5.3 %	0.70	-	246.60	0.70
Q2 2020	192.25	14.5 %	0.55	-	192.25	0.55
Q3 2020	298.80	50.9 %	0.85	-	298.80	0.85
Q4 2020	317.83	17.6 %	0.91	-	317.83	0.91
2020	1,055.48	21.3 %	3.02	-	1,055.48	3.02
Q1 2021	319.00	29.4 %	0.91	-	319.00	0.91
Q2 2021	325.40	69.3 %	0.93	-	325.40	0.93
Q3 2021	348.62	16.7 %	1.00	-	348.62	1.00
Q4 2021	383.59	20.7 %	1.10	-	383.59	1.10
2021	1,376.62	30.4 %	3.93	-	1,376.62	3.93
Q1 2022	390.51	22.4 %	1.12	-	390.51	1.12
Q2 2022	398.13	22.4 %	1.14	-	398.13	1.14
Q3 2022	420.62	20.7 %	1.20	-	420.62	1.20
Q4 2022	441.50	15.1 %	1.26	-	441.50	1.26
2022	1,650.75	19.9 %	4.72	-	1,650.75	4.72
Q1 2023	489.27	25.3 %	1.40	-	489.27	1.40
Q2 2023	486.97	22.3 %	1.39	-	486.97	1.39
Q3 2023	544.77	29.5 %	1.56	-	544.77	1.56
Q4 2023	525.01	18.9 %	1.50	57.58	467.43	1.34
2023	2,046.01	23.9 %	5.85	57.58	1,988.44	5.68
Q1 2024	550.95	12.6 %	1.57	-	550.95	1.57
Q2 2024	555.03	14.0 %	1.59	-	555.03	1.59
Q3 2024	595.54	9.3 %	1.70	-	595.54	1.70

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
2014	-	-	-	-	-	-
2015	1,328.87	-	3.80	-	1,328.87	3.80
2016	1,009.94	(24.0 %)	2.89	-	1,009.94	2.89
2017	656.17	(35.0 %)	1.87	-	656.17	1.87
2018	801.31	22.1 %	2.29	-	801.31	2.29
2019	870.23	8.6 %	2.49	-	870.23	2.49
2020	1,055.48	21.3 %	3.02	-	1,055.48	3.02
2021	1,376.62	30.4 %	3.93	-	1,376.62	3.93
2022	1,650.75	19.9 %	4.72	-	1,650.75	4.72
2023	2,046.01	23.9 %	5.85	57.58	1,988.44	5.68

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
2015	43.25 %	29.04 %	25.94 %
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
2016	38.80 %	22.35 %	20.75 %
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
2017	28.90 %	19.57 %	14.98 %
Q1 2018	-	-	-
Q2 2018	-	-	-
Q3 2018	-	-	-
Q4 2018	29.69 %	21.84 %	17.47 %
2018	29.69 %	21.84 %	17.47 %
Q1 2019	30.24 %	22.28 %	17.62 %
Q2 2019	30.60 %	22.42 %	17.64 %
Q3 2019	29.97 %	21.82 %	17.14 %
Q4 2019	30.37 %	22.40 %	17.35 %
2019	30.37 %	22.40 %	17.35 %
Q1 2020	29.60 %	22.52 %	17.20 %
Q2 2020	29.83 %	23.35 %	17.52 %
Q3 2020	31.47 %	24.38 %	18.08 %
Q4 2020	31.81 %	24.44 %	18.01 %
2020	31.81 %	24.44 %	18.01 %
Q1 2021	32.42 %	24.53 %	18.15 %
Q2 2021	32.61 %	24.54 %	18.65 %
Q3 2021	32.02 %	24.56 %	18.80 %
Q4 2021	32.14 %	24.56 %	18.99 %
2021	32.14 %	24.56 %	18.99 %
Q1 2022	32.32 %	24.53 %	19.19 %
Q2 2022	32.77 %	24.65 %	19.47 %
Q3 2022	33.08 %	24.69 %	19.85 %
Q4 2022	33.07 %	24.18 %	19.86 %
2022	33.07 %	24.18 %	19.86 %
Q1 2023	33.31 %	24.34 %	20.28 %
Q2 2023	33.51 %	24.58 %	20.69 %
Q3 2023	33.84 %	24.81 %	21.16 %
Q4 2023	34.39 %	25.33 %	20.91 %
2023	34.39 %	25.33 %	20.91 %
Q1 2024	34.60 %	25.28 %	21.09 %
Q2 2024	34.59 %	25.19 %	21.13 %
Q3 2024	34.24 %	24.93 %	20.54 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2014	-	-	-
2015	43.25 %	29.04 %	25.94 %
2016	38.80 %	22.35 %	20.75 %
2017	28.90 %	19.57 %	14.98 %
2018	29.69 %	21.84 %	17.47 %
2019	30.37 %	22.40 %	17.35 %
2020	31.81 %	24.44 %	18.01 %
2021	32.14 %	24.56 %	18.99 %
2022	33.07 %	24.18 %	19.86 %
2023	34.39 %	25.33 %	20.91 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
Q1 2018	30.90 %	23.18 %	18.52 %
Q2 2018	27.20 %	19.05 %	14.18 %
Q3 2018	30.93 %	23.14 %	18.15 %
Q4 2018	29.53 %	21.76 %	18.71 %
Q1 2019	32.92 %	24.80 %	19.06 %
Q2 2019	28.92 %	19.88 %	14.52 %
Q3 2019	28.45 %	20.73 %	16.14 %
Q4 2019	31.02 %	23.83 %	19.24 %
Q1 2020	29.77 %	25.06 %	18.36 %
Q2 2020	29.91 %	23.54 %	15.98 %
Q3 2020	34.42 %	24.91 %	18.40 %
Q4 2020	32.27 %	24.14 %	18.79 %
Q1 2021	32.42 %	25.27 %	18.82 %
Q2 2021	31.47 %	23.90 %	18.58 %
Q3 2021	31.93 %	24.92 %	18.98 %
Q4 2021	32.69 %	24.22 %	19.49 %
Q1 2022	33.08 %	25.05 %	19.61 %
Q2 2022	33.31 %	24.45 %	19.77 %
Q3 2022	33.21 %	25.01 %	20.50 %
Q4 2022	32.71 %	22.42 %	19.59 %
Q1 2023	33.97 %	25.51 %	21.21 %
Q2 2023	34.10 %	25.39 %	21.43 %
Q3 2023	34.53 %	25.80 %	22.30 %
Q4 2023	34.91 %	24.64 %	18.80 %
Q1 2024	34.80 %	25.30 %	21.85 %
Q2 2024	34.12 %	25.03 %	21.57 %
Q3 2024	33.33 %	24.77 %	20.01 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
Q1 2015	-	-	-	-
Q2 2015	-	-	-	-
Q3 2015	-	-	-	-
Q4 2015	-	-	-	-
Q1 2016	-	-	-	-
Q2 2016	-	-	-	-
Q3 2016	-	-	-	-
Q4 2016	-	-	-	-
Q1 2017	-	-	-	-
Q2 2017	-	-	-	-
Q3 2017	-	-	-	-
Q4 2017	-	-	-	-
Q1 2018	350.00	-	-	11.82
Q2 2018	350.00	-	-	12.26
Q3 2018	350.00	-	-	12.86
Q4 2018	350.00	2.29	2.29	12.37
Q1 2019	350.00	2.34	2.34	12.43
Q2 2019	350.00	2.39	2.39	11.79
Q3 2019	350.00	2.36	2.36	12.36
Q4 2019	350.00	2.49	2.49	12.55
Q1 2020	350.00	2.52	2.52	13.25
Q2 2020	350.00	2.59	2.59	13.29
Q3 2020	350.00	2.88	2.88	13.74
Q4 2020	350.00	3.02	3.02	14.03
Q1 2021	350.00	3.22	3.22	14.33
Q2 2021	350.00	3.60	3.60	14.56
Q3 2021	350.00	3.75	3.75	14.86
Q4 2021	350.00	3.93	3.93	15.25
Q1 2022	350.00	4.14	4.14	15.67
Q2 2022	350.00	4.35	4.35	15.98
Q3 2022	350.00	4.55	4.55	16.32
Q4 2022	350.00	4.72	4.72	16.80
Q1 2023	350.00	5.00	5.00	17.31
Q2 2023	350.00	5.25	5.25	17.71
Q3 2023	350.00	5.61	5.61	18.27
Q4 2023	350.00	5.85	5.68	18.53
Q1 2024	350.00	6.02	5.86	18.96
Q2 2024	350.00	6.22	6.05	19.43
Q3 2024	350.00	6.36	6.20	19.97

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
2014	-	-	-	-
2015	350.00	3.80	3.80	10.38
2016	350.00	2.89	2.89	12.21
2017	350.00	1.87	1.87	12.34
2018	350.00	2.29	2.29	12.37
2019	350.00	2.49	2.49	12.55
2020	350.00	3.02	3.02	14.03
2021	350.00	3.93	3.93	15.25
2022	350.00	4.72	4.72	16.80
2023	350.00	5.85	5.68	18.53

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Adjusted P/E	Price/book
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
Q1 2018	-	-	-
Q2 2018	-	-	-
Q3 2018	-	-	-
Q4 2018	-	-	-
Q1 2019	-	-	-
Q2 2019	-	-	-
Q3 2019	-	-	-
Q4 2019	-	-	-
Q1 2020	21.77	21.77	4.14
Q2 2020	29.06	29.06	5.67
Q3 2020	33.48	33.48	7.01
Q4 2020	36.14	36.14	7.77
Q1 2021	38.48	38.48	8.65
Q2 2021	45.35	45.35	11.22
Q3 2021	46.46	46.46	11.71
Q4 2021	41.04	41.04	10.58
Q1 2022	46.02	46.02	12.15
Q2 2022	44.60	44.60	12.13
Q3 2022	45.70	45.70	12.74
Q4 2022	46.77	46.77	13.13
Q1 2023	58.30	58.30	16.83
Q2 2023	54.49	54.49	16.16
Q3 2023	42.02	42.02	12.90
Q4 2023	48.58	49.99	15.33
Q1 2024	50.81	52.24	16.14
Q2 2024	46.17	47.42	14.77
Q3 2024	46.62	47.86	14.85

Period	P/E	Adjusted P/E	Price/book
2014	-	-	-
2015	-	-	-
2016	-	-	-
2017	-	-	-
2018	-	-	-
2019	-	-	-
2020	36.14	36.14	7.77
2021	41.04	41.04	10.58
2022	46.77	46.77	13.13
2023	48.58	49.99	15.33

Business Segments (Million)

Compared With The

Period	Hospitals	Pharmacies	Others
Q1 2018	970.00	189.00	10.00
Q2 2018	865.00	174.00	30.00
Q3 2018	908.00	175.00	62.00
Q4 2018	938.00	199.00	68.00
Q1 2019	999.00	208.00	21.00
Q2 2019	916.00	201.00	40.00
Q3 2019	984.00	203.00	40.00
Q4 2019	1,102.00	242.00	60.00
Q1 2020	1,053.00	237.00	53.00
Q2 2020	931.00	209.00	63.00
Q3 2020	1,272.00	261.00	91.00
Q4 2020	1,346.00	294.00	52.00
Q1 2021	1,320.00	313.00	62.00
Q2 2021	1,366.00	315.00	70.00
Q3 2021	1,418.00	338.00	80.00
Q4 2021	1,482.00	389.00	97.00
Q1 2022	1,506.00	417.00	68.00
Q2 2022	1,534.00	407.00	73.00
Q3 2022	1,557.00	408.00	87.00
Q4 2022	1,701.00	492.00	61.00
Q1 2023	1,753.00	491.00	63.00
Q2 2023	1,728.00	484.00	60.00
Q3 2023	1,859.00	485.00	99.00
Q1 2024	1,903.00	544.00	74.00
Q2 2024	1,952.00	542.00	80.00
Q3 2024	2,303.00	607.00	67.00

Period	Hospitals	Pharmacies	Others
2015	4,485.00	598.00	40.00
2016	4,157.00	656.00	55.00
2017	3,671.00	680.00	28.00
2018	3,681.00	737.00	170.00
2019	4,001.00	854.00	161.00
2020	4,602.00	1,001.00	259.00
2021	5,586.00	1,355.00	309.00
2022	6,298.00	1,724.00	289.00
2023	7,318.00	1,991.00	199.00

Analysts Estimates (Million)

Item	Q3 2024 (e)	Q3 2024 (a)	Change‬
Average	581.61	595.54	2.40 %

Estimates vs Actual (Million)

Item	Q3 2024 (e)	Q3 2024 (a)	Change
OSOOL AND BAKHEET	591.26	595.54	0.7 %
Riyad Capital	601.00	595.54	(0.9) %
Al Rajhi Capital	580.00	595.54	2.7 %
Hermes	613.00	595.54	(2.8) %
SNB Capital	578.00	595.54	3.0 %
AlJazira Capital	577.80	595.54	3.1 %
Sico	571.00	595.54	4.3 %
U-Capital	565.40	595.54	5.3 %
United Securities Company	557.00	595.54	6.9 %

Financial Ratios

	Current
Market Cap (M Riyal)	100,310.00
Enterprise Value (EV) (M)	105,278.80
Shares Outstanding ((M))	350.00
EPS ( Riyal) (TTM)	6.36
Book Value (BV) ( Riyal)	19.97
Par Value ( Riyal)	10.00
Adjusted P/E (Last12)	46.25
P/E (TTM)	45.05
Price/book	14.35
Return on Average Assets (%) (TTM)	13.0
Return on Average Equity (%) (TTM)	33.3

Dr. Sulaiman Al Habib Medical Services Group (SULAIMAN ALHABIB)

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Sulaiman Al Habib 9M 2024 profit rises 12% to SAR 1.7B; Q3 at SAR 595.5M

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2024 Q3

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Dr. Sulaiman Al Habib Medical Services Group (SULAIMAN ALHABIB)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

×

Sulaiman Al Habib 9M 2024 profit rises 12% to SAR 1.7B; Q3 at SAR 595.5M

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q3 2024

Revenue by Business Segment (Latest) 2024 Q3

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Dr. Sulaiman Al Habib Medical Services Group (SULAIMAN ALHABIB)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Business Segments (Million)